Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Saglio

Showing results (1-10 of 348) with videos related to

Pageof 35
Sort By:
Clinical Advances in Hematology & Oncology : H&O|May 28, 2010
The best frontline therapy for CML: imatinib?Giuseppe Saglio
Blood|October 31, 2024
Importance of predicting CML therapy failureGiuseppe Saglio
Seminars in Hematology|September 30, 2010
Can we and should we improve on frontline imatinib therapy for chronic myeloid leukemia?Carmen Fava, Giuseppe Saglio
Blood|February 13, 2016
BCR-ABL1 mutation ≠ ponatinib resistanceGiuseppe Saglio, Carmen Fava
Seminars in Hematology|June 5, 2003
Usefulness of quantitative assessment of Wilms tumor suppressor gene expression in chronic myeloid leukemia patients undergoing imatinib therapyDaniela Cilloni, Giuseppe Saglio
Future Oncology (London, England)|December 15, 2018
Nilotinib in the treatment of chronic myeloid leukemiaTomasz Sacha, Giuseppe Saglio
Acta Haematologica|June 5, 2004
WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndromeDaniela Cilloni, Giuseppe Saglio
British Journal of Haematology|August 4, 2023
Interferon in chronic myeloid leukaemia: Is it useful for treatment-free remission?Massimo Breccia, Giuseppe Saglio
Haematologica|February 3, 2004
Conventional and novel tools for defining the risk of the individual patient with chronic myeloid leukemia and for monitoring treatmentGiuseppe Saglio, Daniela Cilloni
Best Practice & Research. Clinical Haematology|December 5, 2009
CML: a model for targeted therapyDaniela Cilloni, Giuseppe Saglio
Pageof 35

Showing results (1-10 of 348) with videos related to

Sort By:
Pageof 35
Clinical Advances in Hematology & Oncology : H&O|May 28, 2010
The best frontline therapy for CML: imatinib?Giuseppe Saglio
Blood|October 31, 2024
Importance of predicting CML therapy failureGiuseppe Saglio
Seminars in Hematology|September 30, 2010
Can we and should we improve on frontline imatinib therapy for chronic myeloid leukemia?Carmen Fava, Giuseppe Saglio
Blood|February 13, 2016
BCR-ABL1 mutation ≠ ponatinib resistanceGiuseppe Saglio, Carmen Fava
Seminars in Hematology|June 5, 2003
Usefulness of quantitative assessment of Wilms tumor suppressor gene expression in chronic myeloid leukemia patients undergoing imatinib therapyDaniela Cilloni, Giuseppe Saglio
Future Oncology (London, England)|December 15, 2018
Nilotinib in the treatment of chronic myeloid leukemiaTomasz Sacha, Giuseppe Saglio
Acta Haematologica|June 5, 2004
WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndromeDaniela Cilloni, Giuseppe Saglio
British Journal of Haematology|August 4, 2023
Interferon in chronic myeloid leukaemia: Is it useful for treatment-free remission?Massimo Breccia, Giuseppe Saglio
Haematologica|February 3, 2004
Conventional and novel tools for defining the risk of the individual patient with chronic myeloid leukemia and for monitoring treatmentGiuseppe Saglio, Daniela Cilloni
Best Practice & Research. Clinical Haematology|December 5, 2009
CML: a model for targeted therapyDaniela Cilloni, Giuseppe Saglio
Pageof 35